文献速递中毒与环境急症消化、代谢与肾脏急症

对乙酰氨基酚中毒肝毒性风险预测

Risk prediction of hepatotoxicity in paracetamol poisoning.
PubMed 文献 · Clin Toxicol (Phila) · 2017-04-27
一句话结论对乙酰氨基酚中毒后,对乙酰氨基酚-转氨酶乘积可用于分层肝毒性风险,新型生物标志物有前景但需进一步验证。

本文系统综述了1974年1月至2016年5月间对乙酰氨基酚中毒肝毒性风险预测工具的文献,共纳入60篇相关文章。对乙酰氨基酚治疗列线图主要用于决定是否需要乙酰半胱氨酸治疗,较少用于预测已治疗患者的肝毒性风险。摄入剂量>12 g或血清浓度超过列线图治疗阈值与肝毒性风险增加相关。对乙酰氨基酚-转氨酶乘积(<1500低风险,1500-10,000低至中度风险,>10,000 mg/L×IU/L高风险)可作为替代策略定义肝损伤风险。新型生物标志物在早期识别肝损伤高风险患者方面显示前景,但需进一步验证。

要点

  • 对乙酰氨基酚-转氨酶乘积<1500 mg/L×IU/L为低风险,1500-10,000为低至中度风险,>10,000 mg/L×IU/L为高风险。
  • 摄入剂量>12 g或血清对乙酰氨基酚浓度超过列线图治疗阈值与肝毒性风险增加相关。
  • 在过量后8小时内接受乙酰半胱氨酸治疗且乘积<10,000 mg/L×IU/L的患者发生肝毒性的可能性低。
  • 对乙酰氨基酚-转氨酶乘积<1500 mg/L×IU/L可能识别适合缩短乙酰半胱氨酸疗程的患者。
  • 新型生物标志物在早期识别肝损伤高风险患者方面显示前景,但需进一步验证和更广泛的临床可及性。

适用人群与场景

  • 对乙酰氨基酚(扑热息痛)中毒患者。

诊断标准与关键阈值

  • 对乙酰氨基酚-转氨酶乘积<1500 mg/L×IU/L为低风险,1500-10,000 mg/L×IU/L为低至中度风险,>10,000 mg/L×IU/L为高风险。
  • 摄入剂量>12 g或血清对乙酰氨基酚浓度超过对乙酰氨基酚列线图治疗阈值与肝毒性风险增加相关。
  • 若患者在过量后8小时内就诊,可进行系列血液检测以获得最终特异性;若就诊时间超过过量后8小时,可进行单次血液检测。

处置流程与药物剂量

  • 对乙酰氨基酚治疗列线图用于帮助决定是否需要乙酰半胱氨酸治疗。
  • 在无法获得肝毒性风险列线图时,可替代使用对乙酰氨基酚-转氨酶乘积来定义肝损伤风险。
  • 在过量后8小时内接受乙酰半胱氨酸治疗且乘积<10,000 mg/L×IU/L的患者发生肝毒性的可能性低。
  • 对乙酰氨基酚-转氨酶乘积<1500 mg/L×IU/L可能识别适合缩短乙酰半胱氨酸疗程的患者。

研究设计与关键结果

  • 系统综述纳入1974年1月至2016年5月间60篇相关文献。
  • 对乙酰氨基酚治疗列线图已使用数十年帮助决定是否需要乙酰半胱氨酸,但较少用于确定治疗后肝毒性风险。
  • 摄入剂量>12 g或血清对乙酰氨基酚浓度超过列线图治疗阈值与肝毒性风险增加相关。
  • 发生更严重肝毒性的患者对乙酰氨基酚消除半衰期更可能延长,但半衰期变异大,作为阴性风险预测工具不敏感。
  • 初始凝血酶原时间正常与肝毒性风险较低相关,但不能单独用于识别不需要乙酰半胱氨酸治疗的患者。
  • 就诊时丙氨酸转氨酶活性正常与对乙酰氨基酚中毒后肝毒性高阴性预测值相关。
  • Psi参数考虑摄入时间、血清对乙酰氨基酚浓度和开始乙酰半胱氨酸治疗时间,基于该参数的肝毒性风险列线图可能更易使用,但仅限于急性摄入。
  • 对乙酰氨基酚-转氨酶乘积<1500 mg/L×IU/L为低风险,1500-10,000 mg/L×IU/L为低至中度风险,>10,000 mg/L×IU/L为高风险。

证据类型、等级与局限

  • 证据类型:系统综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 风险预测工具可分层识别更可能发生肝毒性的患者;目前对乙酰氨基酚-转氨酶乘积可能是这样的工具。
  • 新型生物标志物显示前景,但需进一步验证和更广泛的临床可及性。
  • 这些工具可能有助于为修改乙酰半胱氨酸疗程的临床试验提供信息。

指南或共识出处

  • 对乙酰氨基酚治疗列线图
  • 基于Psi参数的肝毒性风险列线图

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: Paracetamol (acetaminophen) poisoning is the most common cause of acute liver failure in the developed world. A paracetamol treatment nomogram has been used for over four decades to help determine whether patients will develop hepatotoxicity without acetylcysteine treatment, and thus indicates those needing treatment. Despite this, a small proportion of patients still develop hepatotoxicity. More accurate risk predictors would be useful to increase the early detection of patients with the potential to develop hepatotoxicity despite acetylcysteine treatment. Similarly, there would be benefit in early identification of those with a low likelihood of developing hepatotoxicity, as this group may be safely treated with an abbreviated acetylcysteine regimen.

AIM: To review the current literature related to risk prediction tools that can be used to identify patients at increased risk of hepatotoxicity.

METHODS: A systematic literature review was conducted using the search terms: "paracetamol" OR "acetaminophen" AND "overdose" OR "toxicity" OR "risk prediction rules" OR "hepatotoxicity" OR "psi parameter" OR "multiplication product" OR "half-life" OR "prothrombin time" OR "AST/ALT (aspartate transaminase/alanine transaminase)" OR "dose" OR "biomarkers" OR "nomogram". The search was limited to human studies without language restrictions, of Medline (1946 to May 2016), PubMed and EMBASE. Original articles pertaining to the theme were identified from January 1974 to May 2016. Of the 13,975 articles identified, 60 were relevant to the review. Paracetamol treatment nomograms: Paracetamol treatment nomograms have been used for decades to help decide the need for acetylcysteine, but rarely used to determine the risk of hepatotoxicity with treatment. Reported paracetamol dose and concentration: A dose ingestion >12 g or serum paracetamol concentration above the treatment thresholds on the paracetamol nomogram are associated with a greater risk of hepatotoxicity. Paracetamol elimination half-life: Patients with more severe hepatotoxicity are more likely to have a longer paracetamol elimination half-life. While median elimination half-life increases in those developing hepatotoxicity, there is wide variation in half-life, making this an insensitive parameter to use as a negative risk prediction tool. Prothrombin time (PT): An initially normal PT is associated with a lower risk of developing hepatotoxicity, but cannot be used alone to identify patients not requiring acetylcysteine treatment. Hepatic aminotransferase activity: A normal ALT activity on presentation is associated with a high negative predictive value of hepatotoxicity following paracetamol-poisoning. Psi parameter: The psi parameter takes into account the time from ingestion, the serum paracetamol concentration and the time to initiation of acetylcysteine. A hepatotoxicity risk nomogram based on this parameter may be easier to use, but is limited to acute ingestions. Paracetamol-aminotransferase multiplication product: If a hepatotoxicity risk nomogram is not available, an alternate strategy may be to use the paracetamol-aminotransferase product (<1500 low risk, 1500-10,000 low to moderate risk, >10,000 mg/L × IU/L high risk) to define liver injury risk. Serial blood tests can be performed if patients present prior to 8 h post-overdose for ultimate specificity, or a single blood test can be taken if presenting more than 8 h post-overdose. Patients receiving acetylcysteine within 8 h of their overdose, with a product less than 10,000 mg/L × IU/L have a low likelihood of developing hepatotoxicity. Any clinical trials of intensified treatment (e.g., higher dose) to prevent fulminant hepatic failure might potentially use a product of >10,000 mg/L × IU/L as a criterion for inclusion. The paracetamol-aminotransferase product <1500 mg/L × IU/L may also identify those suitable for an abbreviated acetylcysteine regimen. Newer biomarkers: These show promise in the early identification of patients with a higher risk of developing hepatic injury. Point of care devices measuring paracetamol adducts need further trials.

CONCLUSIONS: Risk prediction tools can stratify those that are more likely to develop hepatotoxicity. Currently, the paracetamol-aminotransferase multiplication product may be such a tool. Novel biomarkers show promise but need further validation and greater clinical availability. These tools may help inform clinical trials on modified acetylcysteine regimens.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Wong A, Graudins A. Risk prediction of hepatotoxicity in paracetamol poisoning. Clin Toxicol (Phila). 2017. PMID: 28447858. doi:10.1080/15563650.2017.1317349

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。